Hey Market Enthusiast,

MAIA is already over $2 and the market is clearly reacting to the fresh Diamond Equity update note and what it highlights: first patient dosed in the pivotal Phase 3 THIO 104 trial, plus insider participation in the recent financing. (6)(8)

Action is confirming it too: shares hit $2.23 intraday and were up about 28% this morning, with volume already north of 1.7M.

That’s the kind of “new chapter” trigger that can turn today into a frenzy. 

If you blink on days like this, you usually end up reading about it later instead of watching it happen live.

(2)

The Mathematical Disconnect: $1.74 vs $12.14 (1)(3)(4)(7)

Let’s look at the cold, hard data first. Right now, the data shows this ticker sitting around the $1.74 level. However, if you look at the consensus from the research analysts who actually live and breathe this sector, the picture is radically different.

The average price target is currently $12.14.

That is not a typo. We are looking at an almost 600% potential upside just to reach what the experts consider "fair value." And remember: that $12.14 figure is the average target. It doesn't even account for the most optimistic blue sky scenarios. When you see a gap this wide between the current price and professional valuations, you aren't just looking at a price point. You are looking at a massive coiled spring ready to snap.

The Ultimate Conviction: 19.81% Insider Ownership (2)(5)(7)

In the world of small cap biotech, talk is cheap. Conviction is measured in equity. One of the most glaringly bullish signals in the entire MAIA story is the level of insider alignment. Insiders currently hold 19.81% of the total shares. Think about that for a second. The people running the clinical trials, the ones sitting in the boardrooms, and the ones seeing the raw data months before the public, own nearly a fifth of the company. They aren't just collecting a paycheck. They are personally positioned for the success of this technology. When management has that much "skin in the game," it tells you everything you need to know about their confidence in the upcoming readouts.

The Technology: Rewriting the Rules of Oncology (2)(4)(5)(6)

MAIA Biotechnology (NYSE American: MAIA) is attacking cancer at its very foundation. Their lead candidate, THIO (ateganosine), is a first in class molecule that targets telomeres. For those who aren't biologists: telomeres are the protective caps on the ends of chromosomes. Cancer cells use an enzyme called telomerase to keep these caps long, which essentially makes the cancer cells "immortal."

THIO changes the game. It gets incorporated into those caps and causes selective cancer cell death. But it goes a step further. It also triggers an immune response that turns "cold" tumors "hot," allowing the body’s own immune system to join the fight. This dual mechanism is exactly why the clinical results have been so staggering.

(2)

The Recent Momentum: A Quarter of Dominance (2)(4)(5)(6)

The last few months have been a masterclass in execution. MAIA hasn't just been planning, they have been delivering:
 

• Phase 3 Launch: In December, the company officially treated the first patient in their pivotal THIO-101 Phase 3 study. This is the final major step before potential regulatory approval.
• FDA Fast Track: The FDA has already granted Fast Track designation for THIO in non small cell lung cancer. This means a faster path to the market and more frequent communication with the regulators.
• Global Expansion: They have expanded their clinical trials into Europe and Asia, creating a truly global data set that increases the value of their intellectual property.
   

The Data: 3x Survival Advantage (2)(4)(5)(6)
 

The Phase 2 results for THIO are nothing short of a breakthrough. In a patient population that had already failed multiple previous treatments, the results were definitive. We are looking at a Median Overall Survival of 17.8 months.

Compare that to the current standard of care chemotherapy, which typically shows survival of only 5.8 months.

MAIA is delivering triple the survival time for patients who had run out of options. They are seeing an 88% Disease Control Rate. These aren't just incremental improvements. These are the kind of numbers that redefine an entire sector.

(2)

The Strategic Alliances: Validation from the Giants (2)(4)(5)(6)

MAIA isn't doing this in a vacuum. They have secured clinical supply agreements with the titans of the industry: Roche, Regeneron, and BeOne Medicines. 

These multi billion dollar companies are providing their own proprietary compounds for combination trials with THIO at no cost to MAIA.

When the biggest names in healthcare are willing to partner and provide resources, it serves as a massive third party validation of MAIA's potential. They see what we see.

The FOMO Factor: Why the $1.74 Level Won't Last (1)(2)(3)(4)(5)(6)

We have all seen this play out before. A ticker consolidates at a low level while the big players accumulate. Then, a single piece of news hits the wire and the price gaps up 50% or 100% before the average retail participant can even log into their account.

We even saw it last week with our two big winners. One ripped over 850% from the previous close to the high on the day we alerted you. Then another one ripped 30% over that same period.

With the pivotal Phase 3 now underway and a $12.14 average target looming overhead, the $1.74 entry point is looking more enticing. The momentum, enthusiasm, and analyst optimism is clearly building. 

Final Perspective (1)(3)(4)(5)(6)(7)

The facts are on the table. You have a past winner that is now armed with 3x survival data, massive insider ownership, and Big Pharma partnerships. You have a current price of $1.74 and an analyst consensus of $12.14.

The narrative keeps growing and becomes more robust daily. The clinical milestones are being met. The only question left is where you will be when the market finally wakes up to the MAIA potential.

Keep your eyes locked on MAIA Biotechnology (NYSE American: MAIA). The next leg of this journey is starting now! ⏳

Stay informed. Stay sharp.

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/3LqsROV
2. https://bit.ly/49Pbnnt
3. https://bit.ly/4sSDZ84
4. https://bit.ly/3LRvw4g
5. https://ir.maiabiotech.com/
6. https://maiabiotech.com/
7. https://finance.yahoo.com/quote/MAIA/
8. https://finance.yahoo.com/news/diamond-equity-research-releases-note-130000503.html

Momentum Media LLC has not been compensated for today's profile on MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been previously hired for a period beginning on 01/19/2026 and ending on 01/20/2026 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology Inc. (MAIA:US). Momentum Media LLC has been compensated $10,000.00 and are owed an additional $0 for the Campaign. To date, we have been paid $89,600.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.